RCKT logo

RCKTRocket Pharmaceuticals Inc

$2.94
$0.02
(0.69%)
Today
Updated: 01:20 PM EDT
Reported EarningsMay 7
Mkt Cap$318.85M
Vol1.26M
News
all
press releases
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and...
Business Wire
News Placeholder
More News
News Placeholder
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where's the Stock Going?
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where's the Stock Going...
Yahoo! Finance: News
News Placeholder
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Zacks
News Placeholder
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need...
Business Wire
News Placeholder
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease...
Business Wire
News Placeholder
Lifesci Capital Has Pessimistic Outlook of RCKT Q1 Earnings
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Lifesci Capital cut their Q1 2026 EPS estimates for shares of Rocket Pharmaceuticals in a research report issued on Thursday, April 16th...
MarketBeat
News Placeholder
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by Brokerages
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) has received a consensus rating of "Hold" from the eighteen ratings firms that are presently covering the stock, Marketbeat Ratings...
MarketBeat
News Placeholder
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest Update
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 18,580,923 shares, an increase of 26.5% from the March 15th total of 14,693,507 shares. Currently, 22.6% of the company's...
MarketBeat
News Placeholder
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average - Here's What Happened
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Passes Below 50-Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co.
JPMorgan Chase & Co. lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 73.6% during the third quarter, according to its most recent disclosure with the SEC...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.